Back to news

Smithson Inv.Trust - First day of dealings

Back to news
RNS Number : 5795E
Smithson Investment Trust PLC
19 October 2018

The information contained in this announcement is restricted and is not for publication, release or distribution in the United States of America, any member state of the European Economic Area (other than the United Kingdom and the Republic of Ireland), Canada, Australia, Japan or the Republic of South Africa.

19 October 2018

Smithson Investment Trust plc

First day of dealings

Further to the announcement on 17 October 2018, Smithson Investment Trust plc ("Smithson" or the "Company"), is pleased to announce that 82,250,958 Ordinary Shares will at 8.00 a.m. today be admitted to the premium segment of the Official List and trading on the London Stock Exchange's Main Market for listed securities ("Admission"). The Ordinary Shares will trade under the ticker: SSON (ISIN: GB00BGJWTR88).

The total number of Ordinary Shares in the Company in issue immediately following Admission is 82,250,958 each with equal voting rights. The total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

On Admission:

1.   Terry Smith and other founder partners and key employees of Fundsmith LLP will, directly or indirectly and in aggregate, hold 3.65% of the issued share capital of the Company; and

2.  the Directors and family members will, in aggregate, hold 0.04% of the issued share capital of the Company.

Except where the context requires otherwise, defined terms herein shall have the meanings given to them in the Prospectus published by the Company on 17 September 2018.

The Company's LEI is: 52990070BDK2OKX5TH79.

Enquiries:

Fundsmith LLP

+44 (0)20 3551 6337

Mark Laurence, Chief Operating Officer

Simon Godwin, Chief Financial Officer

 

 

 

Investec Bank plc (Sole Sponsor, Bookrunner, Broker and Intermediaries Offer Adviser)

+44 (0) 20 7597 5970

Darren Vickers

 

David Herring

Helene Comitis

 

 

 

Kepler Communications

+44 (0) 7989 528 421

Charlotte Balbirnie

 

 

 

Important Information

This announcement may not be published, distributed or transmitted by any means or media, directly or indirectly, in whole or in part, in or into the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The securities mentioned in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and will not be offered, sold, exercised, resold, transferred or delivered, directly or indirectly, in or into the United States or to, or for the account or benefit of, any US person (as defined under Regulation S under the US Securities Act). The Company has not been, and will not be, registered under the U.S. Investment Company Act of 1940, as amended.

Neither this announcement nor any copy of it may be: (i) taken or transmitted into or distributed in any member state of the European Economic Area (other than the United Kingdom and the Republic of Ireland), Canada, Australia, Japan or the Republic of South Africa or to any resident thereof, or (ii) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this announcement in other jurisdictions may be restricted by law and the persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCEASENFDLPFEF